ClinicalTrials.gg
CompletedNCT06137703Updated Oct 1, 2024Results posted

A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers

A Phase 1 interventional study of Zavegepant 100mg non-enteric coated soft gel capsule and Zavegepant 100mg immediate release tablet in Biological Availability, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Aug 2022, registered Nov 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This trial is designed to compare the rate and extent of absorption of four different formulations of zavegepant. 52 healthy male and female volunteers will receive a single dose of each formulation at least 7 days apart over a period of about 7 weeks and the amount of drug in their blood will be assessed over the 24 hour period after each dose.

Read the detailed description

This is a Phase 1, single centre, open-label, single dose, 4-period, crossover study designed to compare the pharmacokinetics (PK) of zavegepant from three Test products and a Reference product (treatment D).

52 male and female healthy volunteers will be randomly assigned to one of 4 treatment sequences: ACBD, CDAB, BADC, and DBCA.

In each period, subjects will receive one of the following: Treatment A, B, C, or D on Day 1, followed by 24 hours of PK and safety assessments. On Day 2 subjects will be discharged from the clinical site and instructed to return after at least a 7 day washout time has passed for subsequent periods of treatment.

The study will include a screening visit from Day -28 to Day -2. Eligible subjects will be admitted to the clinical site on Day -1 and will be confined until completion of the assessments on Day 2. There will be a washout period of at least 7 days between doses. Study Exit procedures will be performed after the last assessment on the morning of Day 2 of Period 4. Study Exit procedures will be performed as soon as possible in case of Early Termination.

The total duration of study participation for each subject from Screening through Study Exit is anticipated to be approximately 6.5 weeks.

02

Conditions studied

  • Biological Availability
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must provide Form (ICF) obtained prior to the conduct of any study activities.
  • Healthy Male or female participants at least 18 and less than 56 years of age,
  • Participants must be Non-smokers and not have used any nicotine-containing products for 3 months prior to screening.
  • (BMI) >18.5 and \<30.0kg/m2 and body weight ≥ 50.0kg for males and ≥ 45.0kg for females.
  • All females participants must not be breastfeeding and have a negative urine pregnancy test at Screening.
  • Females of must be willing to use acceptable methods throughout the study and for 30 days after the last study drug administration.
  • Male participants with a female partner of childbearing potential must be willing to use acceptable contraceptive methods from the first study drug administration until at least 90 days after the last study drug administration.

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of viral hepatitis or a history of liver disease.
  • Any history of seizure disorder (e.g., epilepsy) other than a single childhood febrile seizure.
  • Current or recent (within 3 months of the first study drug administration) gastrointestinal disease that may interfere with drug absorption.
  • Prior gastrointestinal surgery that interferes with absorption and motility (e.g., gastric bypass, duodenectomy or gastric banding).
  • History of drug or alcohol abuse.
  • History of anaphylaxis, a documented reaction, or a reaction to any drug or to any of the supporting the zavegepant formulations.
  • Donation of plasma within 7 days prior to dosing, or donation or loss of blood (excluding volume drawn at Screening) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to dosing.
  • Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to the dosing, extended to 90 days for biological products.
  • Inability or difficulty to swallow tablets or capsules.
  • Subjects with any clinically significant abnormality or significant abnormal laboratory test results found during medical screening or Day-1. Positive test for (HIV), surface antigen (HBsAg), or virus (HCV) antibody during screening.
  • Inadequate renal function - estimated (eGFR) according to the Modification of Diet in Renal Disease (MDRD) study equation ≤ 60 mL/min/1.73 m2 at Screening.
  • Any of the following laboratory parameters greater than the (ULN) values at Screening or Baseline (Day -1): alkaline phosphatase (ALP) (AST), alanine aminotransferase (ALT), total , direct bilirubin, and indirect bilirubin, and alkaline phosphatase.
  • Any clinically significant abnormalities on 12-lead or blood pressure (BP) at Screening or Baseline (Day -1) visits.
  • Any clinically significant abnormal haematological laboratory test values at Screening or Baseline (Day -1) visits.
  • Positive test for COVID-19 performed on Day -1 of each period.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Period 1 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 2 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 4 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D).

    Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule

  • Experimental
    Sequence 2

    Period 1 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 2 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 3 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg immediate release tablet (Treatment B).

    Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule

  • Experimental
    Sequence 3

    Period 1 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A) followed by at least 7 days washout; Period 3 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 4 - Two zavegepant 100mg immediate release tablets (Treatment C).

    Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule

  • Experimental
    Sequence 4

    Period 1 - Four zavegepant 25mg enteric coated soft gel capsule (Treatment D) followed by at least 7 days washout; Period 2 - Single zavegepant 100mg immediate release tablet (Treatment B) followed by at least 7 days washout; Period 3 - Two zavegepant 100mg immediate release tablets (Treatment C) followed by at least 7 days washout; Period 4 - Single zavegepant 100mg non-enteric coated soft gel capsule (Treatment A).

    Drug: Zavegepant 100mg non-enteric coated soft gel capsule · Drug: Zavegepant 100mg immediate release tablet · Drug: Zavegepant 2 x 100mg immediate release tablets · Drug: Zavegepant 4 x 25mg enteric coated soft gel capsule

Interventions

  • Zavegepant (PF-07930207/BHV3500) 100mg non-enteric coated soft gel capsule

    Also known as: Treatment A

  • Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablet

    Also known as: Treatment B

  • DrugZavegepant 2 x 100mg immediate release tablets

    2 x Zavegepant (PF-07930207/BHV3500) 100mg dodecylmaltoside dosage form immediate release tablets - total dose 200mg

    Also known as: Treatment C

  • DrugZavegepant 4 x 25mg enteric coated soft gel capsule

    Zavegepant (PF-07930207/BHV3500) 25 mg enteric coated soft gel capsules - total dose 100mg

    Also known as: Treatment D

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant

    AUCinf was calculated as AUClast+(Clast\*/kel), where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using Linear/Log trapezoidal method.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

  2. Maximum Observed Concentration (Cmax) of Zavegepant

    Cmax was observed directly from data.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

  3. AUClast of Zavegepant

    AUClast was calculated using linear/log trapezoidal method.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

Secondary outcomes

  1. Time to Reach Cmax (Tmax) of Zavegepant

    Tmax was observed directly from data as time of first occurrence.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

  2. Terminal Phase Half-Life (t1/2) of Zavegepant

    t1/2 was calculated as Log e(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

  3. Apparent Clearance (CL/F) of Zavegepant From Plasma

    CL/F was calculated as dose/AUCinf. AUCinf was calucalted as AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using linear/log trapezoidal method.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose

  4. Apparent Volume of Distribution (Vz/F) of Zavegepant

    Vz/F was calculated by Dose/(AUCinf×kel). AUCinf was calculated by AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using the linear/log trapezoidal method.

    Time frame: Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Adverse evetn (AE)=any untoward medical occurrence in a patient or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. TEAEs=AEs between first dose of study treatment and up to the end of study participation that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were adjudicated according to the investigator's assessment. Treatment-related was classified based on medical judgement. Severe=Incapacitating with inability to carry out usual activities or significantly affects clinical status, and requires specific action and/or medical attention.

    Time frame: Baseline up to study exit (approximately 6.5 weeks)

  6. Number of Participants With Clinically Significant Laboratory Abnormalities

    Clinically significant laboratory abnormalities were identified as Grade 3 to 4 laboratory test results graded according to numeric laboratory test criteria in the latest version of Common Technical Criteria for Adverse Events (CTCAE) if available, otherwise according to the latest version of Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version. Clinically significant laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last results (scheduled or unscheduled) obtained prior to the first drug administration.

    Time frame: Baseline up to study exit (approximately 6.5 weeks)

  7. Blood Pressure on Day -1 and Day 1 of Each Period

    Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for systolic blood pressure (SBP)=90-140 mm Hg; normal range for diastolic blood pressure (DBP)=50-90 mm Hg.

    Time frame: Day -1, pre-dose and 2 hours post dose on Day 1 of each period

  8. Blood Pressure at Screening and Study Exit

    Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for SBP=90-140 mm Hg; normal range for DBP=50-90 mm Hg.

    Time frame: Screening and study exit

  9. Heart Rate (HR) on Day -1 and Day 1 of Each Period

    HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.

    Time frame: Day -1, pre-dose and 2 hours post dose on Day 1 of each period

  10. HR at Screening and Study Exit

    HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.

    Time frame: Screening and study exit

  11. Respiratory Rate (RR) on Day -1 of Each Period

    RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.

    Time frame: Day -1 of each period

  12. RR at Screening and Study Exit

    RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.

    Time frame: Screening and study exit

  13. Temperature on Day -1 of Each Period

    Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.

    Time frame: Day -1 of each period

  14. Temperature at Screening and Study Exit

    Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.

    Time frame: Screening and study exit

  15. Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG)

    ECG was measured after the participants had been resting for at least 5 minutes in a seated position.

    Time frame: Screening up to study exit (approximately 6.5 weeks)

07

Results

Posted Oct 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneSequence DBCASequence BADCSequence ACBDSequence CDAB
Started13131313
Completed13121213
Not completed0110
Withdrew: Other0100
Withdrew: Adverse event0010

Outcome measures

PrimaryArea Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant

AUCinf was calculated as AUClast+(Clast\*/kel), where AUClast is the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using Linear/Log trapezoidal method.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter (h*ng/mL)
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant
Hours*nanograms per milliliter (h*ng/mL)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of Zavegepant83.65 ± 52102.5 ± 66184.4 ± 7347.29 ± 51
PrimaryMaximum Observed Concentration (Cmax) of Zavegepant

Cmax was observed directly from data.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration (Cmax) of Zavegepant
ng/mLTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Maximum Observed Concentration (Cmax) of Zavegepant36.28 ± 6841.20 ± 8076.93 ± 7712.78 ± 82
PrimaryAUClast of Zavegepant

AUClast was calculated using linear/log trapezoidal method.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Geometric mean · h*ng/mL
AUClast of Zavegepant
h*ng/mLTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
AUClast of Zavegepant82.13 ± 5496.25 ± 66175.5 ± 7242.25 ± 54
SecondaryTime to Reach Cmax (Tmax) of Zavegepant

Tmax was observed directly from data as time of first occurrence.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Median · Hours
Time to Reach Cmax (Tmax) of Zavegepant
HoursTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Time to Reach Cmax (Tmax) of Zavegepant0.9830 (0.483 to 3.00)0.5000 (0.250 to 2.62)0.5000 (0.233 to 2.48)2.000 (0.483 to 5.00)
SecondaryTerminal Phase Half-Life (t1/2) of Zavegepant

t1/2 was calculated as Log e(2)/kel, where kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Mean · Hours
Terminal Phase Half-Life (t1/2) of Zavegepant
HoursTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Terminal Phase Half-Life (t1/2) of Zavegepant8.346 ± 1.31018.907 ± 2.36118.243 ± 1.30049.149 ± 1.5552
SecondaryApparent Clearance (CL/F) of Zavegepant From Plasma

CL/F was calculated as dose/AUCinf. AUCinf was calucalted as AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using linear/log trapezoidal method.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post-dose
Reported as:
Geometric mean · liters per hour (L/h)
Apparent Clearance (CL/F) of Zavegepant From Plasma
liters per hour (L/h)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Apparent Clearance (CL/F) of Zavegepant From Plasma1195 ± 52975.5 ± 661085 ± 732115 ± 51
SecondaryApparent Volume of Distribution (Vz/F) of Zavegepant

Vz/F was calculated by Dose/(AUCinf×kel). AUCinf was calculated by AUClast+(Clast\*/kel), where Clast\* is the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis, and kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. AUClast was calculated using the linear/log trapezoidal method.

Time frame:
Pre-dose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, and 24 hours post dose
Reported as:
Geometric mean · L
Apparent Volume of Distribution (Vz/F) of Zavegepant
LTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Apparent Volume of Distribution (Vz/F) of Zavegepant14230 ± 6012250 ± 7912740 ± 8527530 ± 59
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

Adverse evetn (AE)=any untoward medical occurrence in a patient or clinical trial participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. TEAEs=AEs between first dose of study treatment and up to the end of study participation that were absent before treatment or that worsened relative to pretreatment state. A serious TEAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. SAEs were adjudicated according to the investigator's assessment. Treatment-related was classified based on medical judgement. Severe=Incapacitating with inability to carry out usual activities or significantly affects clinical status, and requires specific action and/or medical attention.

Time frame:
Baseline up to study exit (approximately 6.5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Participants with at least 1 TEAE3243
Participants with at least 1 treatment-related TEAE1010
Participants with at least 1 Severe TEAEs1001
Participants with at least 1 Serious TEAEs1000
SecondaryNumber of Participants With Clinically Significant Laboratory Abnormalities

Clinically significant laboratory abnormalities were identified as Grade 3 to 4 laboratory test results graded according to numeric laboratory test criteria in the latest version of Common Technical Criteria for Adverse Events (CTCAE) if available, otherwise according to the latest version of Division of Acquired Immunodeficiency Syndrome (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version. Clinically significant laboratory abnormalities with occurrence in at least 1 participant are reported for this outcome measure. Baseline was defined as the last results (scheduled or unscheduled) obtained prior to the first drug administration.

Time frame:
Baseline up to study exit (approximately 6.5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Hematology - Hemoglobin<lower limit of normal1010
Urinalysis - Abnormal Leukocyte Esterase0001
Urinalysis - Abnormal Urine Leukocytes0001
SecondaryBlood Pressure on Day -1 and Day 1 of Each Period

Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for systolic blood pressure (SBP)=90-140 mm Hg; normal range for diastolic blood pressure (DBP)=50-90 mm Hg.

Time frame:
Day -1, pre-dose and 2 hours post dose on Day 1 of each period
Reported as:
Median · millimeter of mercury (mm Hg)
Blood Pressure on Day -1 and Day 1 of Each Period
millimeter of mercury (mm Hg)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
SBP on Day -1115.0 (99 to 137)115.0 (99 to 140)116.5 (94 to 140)116.5 (97 to 138)
Pre-dose SBP on Day 1 of each period113.0 (74 to 132)113.0 (93 to 132)114.0 (92 to 144)114.5 (94 to 138)
SBP at 2 hours post dose on Day 1 of each period113.0 (94 to 150)114.0 (94 to 135)113.5 (91 to 144)113.0 (92 to 137)
DBP at Day -175.0 (62 to 90)77.0 (59 to 89)76.0 (64 to 92)76.0 (60 to 92)
Pre-dose DBP on Day 1 of each period75.0 (52 to 92)76.0 (63 to 90)74.0 (64 to 89)76.0 (63 to 90)
DBP at 2 hours post dose on Day 1 of each period75.0 (57 to 100)76.0 (62 to 97)77.0 (61 to 91)75.0 (66 to 88)
SecondaryBlood Pressure at Screening and Study Exit

Blood pressure was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for SBP=90-140 mm Hg; normal range for DBP=50-90 mm Hg.

Time frame:
Screening and study exit
Reported as:
Median · mm Hg
Blood Pressure at Screening and Study Exit
mm HgAll Participants
SBP at Screening121.5 (102 to 144)
SBP at study exit114.0 (94 to 137)
DBP at Screening82.0 (65 to 91)
DBP at study exit76.0 (63 to 90)
SecondaryHeart Rate (HR) on Day -1 and Day 1 of Each Period

HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.

Time frame:
Day -1, pre-dose and 2 hours post dose on Day 1 of each period
Reported as:
Median · Beats per minute (beats/min)
Heart Rate (HR) on Day -1 and Day 1 of Each Period
Beats per minute (beats/min)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
HR on Day -171.0 (50 to 102)72.0 (49 to 102)73.0 (50 to 99)73.0 (56 to 100)
Pre-dose HR on Day 1 of each period73.0 (51 to 93)74.0 (47 to 99)73.5 (52 to 103)73.5 (51 to 110)
HR at 2 hours post dose on Day 1 of each period71.0 (51 to 97)70.0 (48 to 90)71.0 (48 to 108)70.0 (50 to 99)
SecondaryHR at Screening and Study Exit

HR was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for heart rate=50-100 beats/min.

Time frame:
Screening and study exit
Reported as:
Median · beats/min
HR at Screening and Study Exit
beats/minAll Participants
HR at Screening65.0 (46 to 93)
HR at study exit74.0 (53 to 100)
SecondaryRespiratory Rate (RR) on Day -1 of Each Period

RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.

Time frame:
Day -1 of each period
Reported as:
Median · Breaths per minute (breaths/min)
Respiratory Rate (RR) on Day -1 of Each Period
Breaths per minute (breaths/min)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Respiratory Rate (RR) on Day -1 of Each Period14.0 (12 to 18)14.0 (12 to 16)14.0 (12 to 18)14.0 (12 to 18)
SecondaryRR at Screening and Study Exit

RR was measured after the participants had been resting for at least 5 minutes in a sitting position. Normal range for RR=8-20 breaths/min.

Time frame:
Screening and study exit
Reported as:
Median · breaths/min
RR at Screening and Study Exit
breaths/minAll Participants
RR at Screening14.0 (12 to 16)
RR at study exit14.0 (12 to 18)
SecondaryTemperature on Day -1 of Each Period

Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.

Time frame:
Day -1 of each period
Reported as:
Median · Degree Celsius (℃)
Temperature on Day -1 of Each Period
Degree Celsius (℃)Treatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Temperature on Day -1 of Each Period36.60 (36.1 to 37.6)36.40 (35.9 to 37.0)36.50 (35.9 to 37.2)36.50 (36.1 to 37.4)
SecondaryTemperature at Screening and Study Exit

Temperature was measured after the participants had been resting for at least 5 minutes in a seated position. Normal range for temperature=35.8-37.6 ℃.

Time frame:
Screening and study exit
Reported as:
Median · ℃
Temperature at Screening and Study Exit
℃All Participants
Temperature at Screening36.40 (35.9 to 36.8)
Temperature at study exit36.60 (35.8 to 37.4)
SecondaryNumber of Participants With Clinically Significant Abnormal Electrocardiogram (ECG)

ECG was measured after the participants had been resting for at least 5 minutes in a seated position.

Time frame:
Screening up to study exit (approximately 6.5 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormal Electrocardiogram (ECG)
ParticipantsAll Participants
ECG Mean Heart Rate0
PR Interval, Aggregate0
QRS Duration, Aggregate0
QT Interval, Aggregate0
QTc corrected using Bazett's formula (QTcB) Interval, Aggregate0
QTc corrected using Fridericia's formula (QTcF) Interval, Aggregate0

Adverse events

Collected over Screening up to study exit (approximately 6.5 weeks). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: Zavegepant 100 mg SGC0/51 (0%)1/51 (2%)3/51 (5.9%)
Treatment B: Zavegepant 100 mg IR+DDM0/51 (0%)0/51 (0%)2/51 (3.9%)
Treatment C: Zavegepant 200 mg IR+DDM0/50 (0%)0/50 (0%)4/50 (8%)
Treatment D: Zavegepant 4*25 mg SGC0/50 (0%)0/50 (0%)3/50 (6%)
Most frequent serious events
Most frequent serious events
EventTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Abdominal painGastrointestinal disorders1/510/510/500/50
Pancreatitis acuteGastrointestinal disorders1/510/510/500/50
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTreatment A: Zavegepant 100 mg SGCTreatment B: Zavegepant 100 mg IR+DDMTreatment C: Zavegepant 200 mg IR+DDMTreatment D: Zavegepant 4*25 mg SGC
Skin abrasionInjury, poisoning and procedural complications1/510/512/501/50
Haemoglobin decreasedInvestigations0/511/510/501/50
DizzinessNervous system disorders0/511/511/501/50
SyncopeNervous system disorders0/510/510/501/50
NauseaGastrointestinal disorders0/510/511/500/50
Alanine aminotransferase increasedInvestigations1/510/510/500/50
Aspartate aminotransferase increasedInvestigations1/510/510/500/50
Blood bilirubin increasedInvestigations1/510/510/500/50
Lipase increasedInvestigations1/510/510/500/50
White blood cells urine positiveInvestigations1/510/510/500/50

Baseline characteristics

Included all participants who received at least 1 dose of any study intervention.

Age, Customized
Age, Customized(Years)All Participants
18-65 years of age37.0 (22 to 48)
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female19
Male33
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
Hispanic or Latino51
Not Hispanic or Latino1
Not Reported0
Unknown0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
American Indian0
Asian0
Black11
Hawaiian0
White41
Multiple0
Other0
08

Study locations

1 site
  • Syneos Health Clinical Research Services, Llc
    Miami, Florida 33136, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Dec 2022, 3 months.

Results were first posted in Oct 2024, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Aug 24, 2022
Primary completionActual
Dec 7, 2022
CompletionActual
Dec 7, 2022
Results first posted
Oct 1, 2024
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06137703
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Aug 24, 2022
Primary completion
Dec 7, 2022
Completion
Dec 7, 2022
Results posted
Oct 1, 2024
Last update
Oct 1, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion